Dynavax Technologies  (Nasdaq: DVAX)

A clinical-stage biopharmaceutical company, that discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines.

More on DVAX here

Achillion Pharmaceuticals  (Nasdaq: ACHN)

An innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease – HCV, HIV and resistant bacterial infections.

More on ACHN here

Wizzard Software (AMEX: WZE)

The industry's leading podcasting network, the Company announced that it recorded an unprecedented 1.4 billion podcast download requests in 2009. Wizzard Media, through its premier podcast-hosting service Libsyn, received an average of 3.77 million requests for podcast episodes per day in 2009. On average, 23 minutes per episode equates to almost 1.5 million hours of programming distributed worldwide every day. Wizzard provides publishing and distribution services to podcasters as well as monetization services. 

Podcasts are a means for independent and professional content creators to publish audio and video shows for the world to enjoy over the Internet or on mp3 players, such as the Apple iPod, iPhone and the Microsoft Zune. Podcasting is a relatively new phenomenon, but Wizzard Media collectively broadcasts millions of podcast downloads per day through media aggregators like Apple's iTunes and Microsoft's Zune Marketplace. 

More on WZE here

Micrus Endovascular (Nasdaq: MEND)

Develops, manufactures and markets implantable and disposable medical devices for use in the treatment of cerebral vascular diseases. Micrus products are used by interventional neuroradiologists, interventional neurologists and endovascularly trained neurosurgeons to treat both cerebral aneurysms responsible for hemorrhagic stroke and intracranial atherosclerosis, which may lead to ischemic stroke. 

The company has operations in the Americas, Europe, and the Asia Pacific.

More on MEND here